Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?

Mavridis, Theodoros; Deligianni, Christina I; Karagiorgis, Georgios; Daponte, Ariadne; Breza, Marianthi; Mitsikostas, Dimos D

Mavridis, Theodoros; Deligianni, Christina I; Karagiorgis, Georgios; Daponte, Ariadne; Breza, Marianthi; Mitsikostas, Dimos D.

Afiliação

Mavridis T; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Deligianni CI; Neurology Department, Athens Naval Hospital, 11521 Athens, Greece.
Karagiorgis G; Neurology Department, 401 Military General Hospital, 11525 Athens, Greece.
Daponte A; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Breza M; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Mitsikostas DD; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Pharmaceuticals (Basel) ; 14(7)2021 Jul 20.

Article em En | MEDLINE | ID: mdl-34358126

Palavras-chave

CGRP; calcitonin gene-related peptide; eptinezumab; erenumab; fremanezumab; galcanezumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Grécia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google